ClariTrial | Search Clinical Trials

Explore/neurology CNS brain disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

161 results for “neurology CNS brain disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 11

Recruiting

Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

Phase 2Multiple SclerosisRRMSRelapsing Remitting MS

HP 13C pyruvate injectionMRI Scanner

Ari Green40 participants1 site · United StatesCompletes Dec 2029

Compare CT.gov Full analysis →

Recruiting

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

Phase 2Phase 3Acute StrokeIschemic StrokeStroke

Recombinant human tissue kallikreinPlacebo for DM199 Solution for Injection

DiaMedica Therapeutics Inc728 participants86 sites · United States, Belgium, CanadaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Azathioprine in MOGAD

Phase 3Central Nervous System InflammationMOG-IgG Associated Disease

AzathioprinePlacebo

Hospices Civils de Lyon126 participants17 sites · FranceCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia

Phase 3Friedreich Ataxia

OmaveloxolonePlacebo

Biogen255 participants34 sites · United States, Australia, AustriaCompletes Nov 2027

Compare CT.gov Full analysis →

Recruiting

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

Phase 1Phase 2Lysosomal DiseasesGangliosidosisGM1

AAV9-GLB1Abdominal ultrasoundRituximab+18 more

National Human Genome Research Institute (NHGRI)54 participants1 site · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

Recruiting

Effect of Cilostazol in Promoting Hematoma Clearance After Intracerebral Hemorrhage

Phase 2ICH - Intracerebral Hemorrhage

Pletaal 100mg/tabConventional internal medicine treatment

National Taiwan University Hospital100 participants1 site · TaiwanCompletes Jan 2027

Compare CT.gov Full analysis →

Recruiting

Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache

Phase 3Cluster Headache

Botulinum toxin type Aplacebo

Norwegian University of Science and Technology112 participants5 sites · Germany, Italy, NorwayCompletes Sep 2025

Compare CT.gov Full analysis →

Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

Phase 2AgitationAlzheimer Disease

BMS-986368Placebo

Celgene120 participants75 sites · United States, Argentina, AustraliaCompletes Nov 2027

Compare CT.gov Full analysis →

Recruiting

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Phase 3Alzheimer Disease

Combined metabolic activatorsCollagen and maltodextrin

ScandiBio Therapeutics AB845 participants8 sites · Turkey (Türkiye)Completes Sep 2026

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

Phase 2Parkinson Disease

AP-472Placebo

Appello Pharmaceuticals, Inc.150 participants30 sites · United StatesCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users

Phase 3Acute Ischemic Stroke

Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)Placebo

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University912 participants1 site · ChinaCompletes Sep 2028

Compare CT.gov Full analysis →

Recruiting

Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

Phase 2Parkinson Disease

PlaceboVarenicline

Vikas Kotagal102 participants1 site · United StatesCompletes Jan 2029

Compare CT.gov Full analysis →

Recruiting

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

Phase 2Cognitive DysfunctionLewy Body DiseaseSynucleinopathies

DonanemabPlacebo

Eli Lilly and Company350 participants71 sites · United States, Japan, South KoreaCompletes Aug 2028

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Phase 3Migraine

RimegepantPlacebo

Pfizer640 participants90 sites · United States, Canada, FranceCompletes Nov 2031

Compare CT.gov Full analysis →

Recruiting

Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy

Phase 1Phase 2PARKINSON DISEASE (Disorder)ApathySafety

IRL757Placebo

Integrative Research Laboratories AB75 participants13 sites · Bulgaria, Germany, PolandCompletes May 2027

Compare CT.gov Full analysis →

1–15 of 161

Explore/neurology CNS brain disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

161 results for “neurology CNS brain disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 11

Recruiting

Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

Phase 2Multiple SclerosisRRMSRelapsing Remitting MS

HP 13C pyruvate injectionMRI Scanner

Ari Green40 participants1 site · United StatesCompletes Dec 2029

Compare CT.gov Full analysis →

Recruiting

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

Phase 2Phase 3Acute StrokeIschemic StrokeStroke

Recombinant human tissue kallikreinPlacebo for DM199 Solution for Injection

DiaMedica Therapeutics Inc728 participants86 sites · United States, Belgium, CanadaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Azathioprine in MOGAD

Phase 3Central Nervous System InflammationMOG-IgG Associated Disease

AzathioprinePlacebo

Hospices Civils de Lyon126 participants17 sites · FranceCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia

Phase 3Friedreich Ataxia

OmaveloxolonePlacebo

Biogen255 participants34 sites · United States, Australia, AustriaCompletes Nov 2027

Compare CT.gov Full analysis →

Recruiting

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

Phase 1Phase 2Lysosomal DiseasesGangliosidosisGM1

AAV9-GLB1Abdominal ultrasoundRituximab+18 more

National Human Genome Research Institute (NHGRI)54 participants1 site · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

Recruiting

Effect of Cilostazol in Promoting Hematoma Clearance After Intracerebral Hemorrhage

Phase 2ICH - Intracerebral Hemorrhage

Pletaal 100mg/tabConventional internal medicine treatment

National Taiwan University Hospital100 participants1 site · TaiwanCompletes Jan 2027

Compare CT.gov Full analysis →

Recruiting

Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache

Phase 3Cluster Headache

Botulinum toxin type Aplacebo

Norwegian University of Science and Technology112 participants5 sites · Germany, Italy, NorwayCompletes Sep 2025

Compare CT.gov Full analysis →

Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

Phase 2AgitationAlzheimer Disease

BMS-986368Placebo

Celgene120 participants75 sites · United States, Argentina, AustraliaCompletes Nov 2027

Compare CT.gov Full analysis →

Recruiting

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Phase 3Alzheimer Disease

Combined metabolic activatorsCollagen and maltodextrin

ScandiBio Therapeutics AB845 participants8 sites · Turkey (Türkiye)Completes Sep 2026

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

Phase 2Parkinson Disease

AP-472Placebo

Appello Pharmaceuticals, Inc.150 participants30 sites · United StatesCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users

Phase 3Acute Ischemic Stroke

Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)Placebo

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University912 participants1 site · ChinaCompletes Sep 2028

Compare CT.gov Full analysis →

Recruiting

Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

Phase 2Parkinson Disease

PlaceboVarenicline

Vikas Kotagal102 participants1 site · United StatesCompletes Jan 2029

Compare CT.gov Full analysis →

Recruiting

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

Phase 2Cognitive DysfunctionLewy Body DiseaseSynucleinopathies

DonanemabPlacebo

Eli Lilly and Company350 participants71 sites · United States, Japan, South KoreaCompletes Aug 2028

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Phase 3Migraine

RimegepantPlacebo

Pfizer640 participants90 sites · United States, Canada, FranceCompletes Nov 2031

Compare CT.gov Full analysis →

Recruiting

Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy

Phase 1Phase 2PARKINSON DISEASE (Disorder)ApathySafety

IRL757Placebo

Integrative Research Laboratories AB75 participants13 sites · Bulgaria, Germany, PolandCompletes May 2027

Compare CT.gov Full analysis →

1–15 of 161